<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Rizzo, Toni</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Lin, Nancy U.</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Advances in HER2-Positive Breast Cancer</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2013</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2013-02-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">22-23</style></pages><abstract><style  face="normal" font="default" size="100%">This article discusses discussed major advances in the treatment of human epidermal growth factor 2 (HER2)-positive breast cancer in the past decade, the current state of adjuvant therapy for HER2-positive breast cancer, as well as the therapeutic implications of neoadjuvant therapy for HER2-positive breast cancer.</style></abstract><number><style face="normal" font="default" size="100%">20</style></number><volume><style face="normal" font="default" size="100%">12</style></volume></record></records></xml>